OWNERSHIP OF MICROBIOME-DERIVED INTELLECTUAL PROPERTY

1. INTRODUCTION

Microbiome-derived intellectual property concerns inventions, technologies, and commercial products developed using microorganisms and their interactions with the human body. Examples include probiotics, engineered bacteria, microbiome-based therapeutics, microbial diagnostic methods, enzymes, therapeutic formulations, and algorithms analysing microbial data.

Ownership disputes arise when researchers isolate microorganisms from human samples, employers fund discoveries, universities commercialise research, or companies develop proprietary technologies from biological materials. The central legal question is whether protection belongs to the inventor, employer, research institution, contractual assignee, or another legally entitled party.

Under Indian law, ownership depends on the type of intellectual property involved, the inventorship and assignment arrangements, the source of biological materials, and the applicable statutory restrictions. Ownership of a patentable invention does not automatically confer ownership over a person's body, all microorganisms naturally present in it, or unrestricted rights over donated biological samples.

2. LEGAL FRAMEWORK IN INDIA

A. Patent protection

The Patents Act, 1970 governs patentability and ownership. Sections 2(1)(j) and 2(1)(ja) establish the requirements of invention and inventive step, while Section 3(c) excludes the mere discovery of living things or substances occurring in nature. Section 3(j) excludes specified plants, animals, and essentially biological processes, while expressly treating microorganisms differently.

Accordingly, an isolated naturally occurring bacterium is not automatically patentable merely because it has been discovered. A genuinely engineered microorganism, a novel technical process, or a microbiome-based formulation may qualify if it satisfies all applicable requirements and is not otherwise excluded.

B. Inventorship and ownership

Under Sections 6 and 7 of the Patents Act, a patent application may be made by a person claiming to be the true and first inventor, an assignee, or the legal representative of a deceased person entitled to apply. Section 68 requires specified assignments and interests in patents to be in writing and duly executed to be valid.

Employment agreements, research contracts, funding agreements, and institutional intellectual-property policies therefore play an important role in determining ownership. Funding research does not, by itself, establish that the funder owns every resulting invention.

C. Biological resources and access obligations

The Biological Diversity Act, 2002, as amended, may impose access, approval, intimation, or benefit-sharing requirements in applicable circumstances. The precise obligations depend on the biological resource, the applicant's status, the activity, and the statutory exemptions or exceptions.

Researchers should document the provenance of microbial samples, applicable permissions, material-transfer agreements, consent arrangements, and benefit-sharing obligations. Patent ownership does not automatically extinguish these requirements.

D. Confidentiality and data rights

Trade-secret protection may cover confidential manufacturing methods, microbial formulations, or proprietary analytical processes if the information qualifies for such protection. Copyright may protect original software and database expression, but does not ordinarily confer ownership of biological facts themselves. Human-derived microbiome data may also engage applicable privacy and research-ethics requirements.

3. RELEVANT CASE LAWS

1. Dimminaco A.G. v. Controller of Patents and Designs (2002) — Direct Indian authority

The Calcutta High Court considered whether a process producing a vaccine containing a living virus could be patented. It rejected the proposition that the presence of a living organism necessarily disqualified the process from patent protection. The decision is relevant to microbiome-derived inventions involving living microorganisms, although patentability still depends on the current statutory requirements and the particular claims.

2. Nuziveedu Seeds Ltd. v. Monsanto Technology LLC (Delhi High Court, 2018) — Direct but limited biotechnology-patent authority

The Delhi High Court examined the relationship between biotechnology patents and the exclusions under Section 3(j) of the Patents Act in a dispute involving genetically modified cotton technology. The Supreme Court subsequently set aside the challenged High Court judgment and remanded the matter for trial. The 2018 reasoning must therefore not be treated as a final, binding determination of every issue it discussed. The litigation nevertheless illustrates the importance of distinguishing patentable technical inventions from excluded biological subject matter.

3. Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979) — Direct authority on inventive step

The Supreme Court explained that an invention must involve more than a trivial or obvious modification of existing knowledge. Applied to microbiome technology, merely identifying a known microorganism or making an obvious formulation change may be insufficient to establish inventive step.

4. Diamond v. Chakrabarty (1980) — Analogous United States authority

The United States Supreme Court upheld patent eligibility for a genetically engineered bacterium capable of breaking down multiple components of crude oil. The decision illustrates the distinction between a human-made engineered organism and a naturally occurring organism. It is persuasive comparative authority only; Indian patentability is governed by the Patents Act, 1970.

5. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) — Analogous United States authority

The United States Supreme Court held that naturally occurring DNA does not become patentable merely through isolation, while synthetically created complementary DNA may be patent eligible in the circumstances considered. The judgment is relevant by analogy to claims involving naturally occurring microbial genes and genuinely engineered genetic constructs. It does not determine Indian patentability.

6. Harvard College v. Canada (Commissioner of Patents) (2002) — Analogous Canadian authority

The Supreme Court of Canada rejected patent protection for the higher life form claimed in the case. Although the decision concerned a genetically modified animal rather than microbiome technology, it illustrates how statutory exclusions may limit patent claims involving living organisms. India's express treatment of microorganisms under Section 3(j) requires separate analysis.

4. PRACTICAL OWNERSHIP AND COMPLIANCE REQUIREMENTS

Research institutions and commercial developers should identify inventors accurately, execute written assignments, document sample provenance, and define ownership in collaboration and licensing agreements. Agreements should distinguish patents, software, confidential know-how, biological samples, and research data.

Before commercialisation, developers should assess patent novelty, inventive step, industrial applicability, disclosure requirements, biological-resource obligations, and any applicable consent or benefit-sharing conditions. A patent grants legally defined exclusionary rights over the claimed invention; it does not establish unrestricted ownership of all naturally occurring microbiome components.

5. CONCLUSION

Ownership of microbiome-derived intellectual property in India depends on patentability, inventorship, valid assignment, contractual arrangements, and compliance with biological-resource and privacy requirements. Naturally occurring microorganisms are not automatically patentable, while qualifying engineered organisms, processes, and technical applications may receive protection.

The cited decisions clarify the distinction between discovery and invention, the need for inventive step, and the limits imposed by statutory exclusions. Effective ownership management requires clear documentation of contributions, lawful access to biological materials, enforceable contracts, and careful separation of intellectual-property rights from rights and obligations relating to human biological samples.